Modern Pathology

ModPath Chat

Health EN ↓ 93 episodes

ModPath Chat is the official podcast of Modern Pathology, the journal of the US and Canadian Academy of Pathology (USCAP). ModPath Chat features interviews with authors, opinion leaders and experts on the latest science, technology, and developments in the field of pathology. The monthly podcast series is hosted by Dr. George J. Netto, the Editor-in-Chief of Modern Pathology and the Simon Flexner Professor and Chair, Department of Pathology and Laboratory Medicine at the University of Pennsylvania Perelman School of Medicine in Philadelphia

Be sure to visit the podcast's website and support the creator: www.modernpathology.org

Author

Modern Pathology

Category

Health

Podcast website

www.modernpathology.org

Latest episode

Dec 31, 2024

Where to listen?

Podcasts in the app Replaio Radio Coming soon

Podcasts are coming to the app soon. Install now and be the first to see a whole new take on podcasts

Get it on Google Play Install for free Android almost 10M downloads · 4.8 rating iOS soon

Episodes

Meet the Expert: A Conversation with Professor Reinhard Buttner 19.04.2022

An informative discussion with Dr. Buttner on the significance of newly acquired genetic insights into pulmonary invasive mucinous adenocarcinoma (IMA). In the latest WHO classification, IMA is defined as a primary lung adenocarcinoma with tumor cells showing goblet cell- or columnar cell-morphology with abundant intracytoplasmic mucin. Due to its distinctive clinical features, i.e., peripheral lo...

DP, WSI, AI, DL: The Alphabet Soup of the Third Revolution in Pathology 06.04.2022

Traditional pathology have played an integral role in the delivery of diagnosis, semi-quantitative or qualitative assessment of protein expression, and classification of disease. Technological advances have recently paved the way for the development of digital pathology-based approaches for quantitative pathologic assessments, namely whole slide imaging (WSI) and artificial intelligence (AI)–based...

Atypical Uterine Polyps: A benign clinical course despite morphologic and molecular overlap with Adenosarcomas. 22.03.2022

A subset of clinically benign uterine polyps shows atypical morphologic features worrisome for, but not diagnostic of, Mullerian adenosarcoma. The guest, Dr Marisa Nucci discusses her team’s finding in their recently published study in Modern Pathology. The authors propose the term "atypical uterine polyps" for these lesions, which show biologic overlap with early Mullerian adenosarcoma but l...

Breast Implant Associated Lymphomas: EBV positivity pathogenic role? 08.03.2022

Breast implant anaplastic large cell lymphoma (ALCL) is a T-cell neoplasm arising around textured breast implants. Our host discusses with Drs. Medeiros and Miranda their recent report on eight cases of Epstein–Barr virus (EBV)-positive large B-cell lymphoma associated with breast implants. Their data suggest a pathogenetic role for breast implants (as well as EBV) in the pathogenesis of this type...

Molecular subtypes of Index Vs Metachronous Gastric cancers 22.02.2022

Professor Gregory Lauwers from Moffitt Cancer Center discusses his team’s recent study comparing index and metachronous gastric cancers in 42 Korean patients. Gastric adenocarcinomas were classified into 5 subtypes: EBV-associated, MMR deficient (MMRD), E cadherin aberrant, p53-aberrant [p53(+)], and p53 non-aberrant [p53(neg)]. Although no significant difference in the frequency of most molecular...

Machine Learning facilitates assessment of shaved lumpectomy margins 09.02.2022

Drs. Timothy D’Alfonso, David Ho, and Lee K.Tan from Memorial Sloan Kettering in NY discuss their recent Modern Pathology study describing a new machine learning algorithm that can help pathologists assess shaved margins from lumpectomy specimens. A uniquely developed Deep Multi-Magnification Network (DMMN) was utilized in Whole Slide Images (WSI) in the hope to triage negative margins and al...

Meet the Expert: A Conversation with Professor Holger Moch 25.01.2022

Professor Holger Moch shares with our audience his most inspiring career journey as a physician scientist and a luminary in the field of renal cancers. An enjoyable historical look back at the evolution of the field and the progress in renal tumor classifications.

2021 Year in Review 28.12.2021

In this episode of ModPath CHAT, Dr. George J Netto reviews five of the highly cited manuscripts that were published in Modern Pathology in 2021.

NTRK Fusions 07.12.2021

Identification of molecular alterations in NTRK 1-3 has become increasingly important with the emergence of histology-agnostic, US Food and Drug Administration-approved, effective inhibitors. The host discusses with Dr. Jaclyn Hechtman, director of clinical diagnostic development at Neogenomics, her practical insights on how testing for NTRK fusion can best be implemented and communicated within t...

DICER1 Tumor Predisposition Syndrome: A chat with Pepper Dehner! 23.11.2021

Dr. Dehner discusses his four decades journey with an entity that he first described in 1977. Since his initial description of Pleuropulmonary Blastoma (PPB), the neoplasm has become one of the defining entities of DICER1 Syndrome, a rare autosomal dominant familial tumor predisposition disorder with heterozygous DICER1 germline mutation. A fascinating historical perspective and most informative M...

Re-evaluating tumors of purported specialized prostatic stromal origin: Distinct entities or Heterogenous mesenchymal neoplasms? 09.11.2021

The host is joined by Dr. Andres Acosta from the Brigham and Women Hospital. Dr Acosta discusses, on behalf of a distinguished group of coauthors, their recent somewhat provocative modern pathology publication proposing that mesenchymal neoplasms of the prostate are morphologically and molecularly heterogeneous lesions that include neoplasms that harbor genetic aberrations seen in specific mesench...

"AstroPath" Substituting cells for cosmic stars, the sky is the limit for digital and computational pathology! 26.10.2021

In this special "Meet the Expert" episode, two distinguished guests from Johns Hopkins University discuss their pioneering approach of applying methodologies, initially developed for astronomy, to the assessment of biomarkers of tumor microenvironment (TME). The guests are Dr. Janis Taube, director of Dermatopathology at Hopkins, and a co-Director of the TME Core at the Bloomberg-Kimmel Institute...

Counting Mitoses: SI(ze) matters! 12.10.2021

In this episode, Dr. Ian Cree, Head of The WHO Tumour Classification discusses his team's recent open access publication in Modern Pathology. Historically, mitotic figures counting has been done by expressing the number of mitoses per  n  high power fields (HPFs), ignoring the fact that microscope fields may differ substantially, even at the same high power (×400) magnification. Dr. Cree...

The Role of Genotyping in the Diagnosis and Prognostication of Gestational Trophoblastic Disease 29.09.2021

In this episode of MODPATH CHAT, our guests Dr. Natalia Buza and Dr. Pei Hui from the department of Pathology at Yale University share their approach to the application of DNA genotyping to the diagnosis and prognostication of Hydatidiform moles and Gestational trophoblastic tumors. Genotyping is now the gold standard in the confirmation and subtyping of sporadic hydatidiform moles. DNA genotyping...

Regression predicts Sentinel Lymph Node (SLN) status 14.09.2021

The prognostic significance of regression has long been a matter of debate. Our guest, Professor Richard Scolyer, co-director of the Melanoma Institute Australia discussed his team’s recent findings on the prognostic value of regression, and the presence of regression and/or tumor infiltrating lymphocytes (TIL) in primary cutaneous melanomas predicted sentinel lymph node (SLN)...

A Novel Prognostic Score for NSCLC following Neoadjuvant therapy 31.08.2021

Dr. Sabina Berezowka, from the university of Lausanne Switzerland, discusses with our host her team’s recent study describing a novel "Prognostic Score" for assessing tumor regression following Neaodjuvant therapy in non-small cell lung cancer (NSCLC). The proposed combined prognostic score (PRSC) performed better than pTNM staging and previously published Major Pathologic Response (MPR) approach....

DDIT3 Immunohistochemical expression as a diagnostic marker for Myxoid Liposarcoma 18.08.2021

Dr. Jason Hornick discusses his team recent study finding that a monoclonal antibody directed against the N-terminus of DDIT3 is a highly sensitive and specific for high-grade MLPS. DDIT3 immunostains could replace molecular genetic testing in many cases, although limited labeling may be seen in a range of other tumor types. Study by Hornick et al, Nuclear expression of DDIT3 distinguishes high-gr...

TRIM63 as a biomarker for MiT family RCC 03.08.2021

In this episode Dr. Rohit Mehra of University of Michigan discusses the utility of TRIM63 as a diagnostic marker to distinguish MiTF-RCC from other renal tumor subtypes with overlapping morphology. In combination with TFE3/TFEB FISH, TRIM63 RNA-ISH assays can improve the accuracy and efficiency of MiTF-RCC diagnosis. Study by Mehra et al, TRIM63  is a sensitive and specific biomarker for MiT...

A MODPATH Chat with Dr. Victor Reuter: The Digital Transformation of Anatomic Pathology 20.07.2021

Always a visionary, Dr. Reuter was one of the earliest Anatomic Pathologists to embrace and advance the genomic and more recently the digital transformation of our field. In this episode of Meet The Expert series, Dr. Reuter shares his perspective and vision on the current and future impact of digital pathology

Artificial intelligence for advance requesting of IHC in diagnostically uncertain prostate biopsies 06.07.2021

Dr. Clare Verrill and Andrea Chatrian of Oxford University in England discuss their team’s study on AI for advance ordering of IHC in difficult prostate biopsy. Their elegant work shows that an AI tool making automated IHC request prior to the pathologist read of H&E could create leaner workflow and result in pathologist time savings and shorten overall Turnaround time from accession to final...

Synchronous Endometrial and Ovarian Carcinomas: Clonal relationship and directionality of progression. 22.06.2021

Dr. Britta Weigelt of MSKCC discusses her team’s study on synchronous endometrial (EC) and ovarian carcinomas (OC) in Lynch syndrome and constitutional Mismatch Repair Deficiency Syndrome (CMMRD). Contrary to sporadic synchronous ECs/OCs, which are almost invariably clonally related, ECs/OCs simultaneously involving the uterus and ovary in LS patients may represent two independent primary tumors....

Deciphering the Molecular Underpinning of Ulcerative Colitis Associated Colorectal Cancer 08.06.2021

Dr. Daniela Hirsch, from the Institute of Pathology at the University of Heidelberg in Germany, discusses her findings on the molecular alterations associated with colorectal cancer in the setting of Ulcerative Colitis. Using aCGH, a 48 gene panel and MSI analysis and IHC for TP53, the author and her team revealed high rate of TP53 mutations and gains in chromosome 5p in these predominantly M...

Post Neo-adjuvant Chemotherapy Patterns of Residual Breast Cancer 25.05.2021

Dr. Stuart Schnitt from Brigham and Women Hospital in Boston discusses his team'srecent findings of variable architectural and cytological patterns of residual disease in breast cancer patients with incomplete pathologic response. The relationship of pattern of residual disease to pre-treatment clinicopathologic parameters and the potential impact on management are discussed. Study by Pastorello e...

"Rebranding" Hematopathology Using Twitter: The MD Anderson Experience 11.05.2021

In this episode, our guests, Dr. Siba El Hussein and Dr. Sanam Loghavi from the department of hematopathology at MD Anderson Cancer Ctr, discuss their experience on the role of social media in the dissemination of knowledge in hematopathology and establishing networks of collaborators and followers. Editorial by El Hussein et al, Next-Generation Scholarship: Rebranding Hematopathology Using Twitte...

USCAP 2021 Long Course: Biomarkers of Response to Check Point Inhibitors - beyond PD-L1 27.04.2021

In this fourth and final episode of our special series covering this year’s USCAP Long Course on lung disease, our guest, Dr. Lynette Sholl, chief of pulmonary pathology at the Brigham and Women Hospital discusses her presentation on "Biomarkers of Response to Checkpoint Inhibitors". Dr. Sholl touches upon the potential role of CD8+ T cell count, Multiplex IF based spatial profiling and novel geno...

Listen to the ModPath Chat podcast in Replaio

Radio and podcasts in one app - free, with no sign-up. Install today and do not miss the launch

Get it on Google Play

Replaio is not a podcast publisher; show names, artwork and audio belong to their authors and are distributed through public RSS feeds.